Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 17/20 | 0.46 |
| ▸ | HSD11B2 | P80365 | 2/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL942696 | 1.00 | HSD11B1 (0.46) | HSD11B1HSD11B2EPHX2 | |
| SCHEMBL10046791 | 1.00 | HSD11B1 (0.46) | HSD11B1HSD11B2EPHX2 | |
| Trifluoroacetic Acid SCHEMBL30702753 | 0.85 | HSD11B1 (0.47) | HSD11B1HSD11B2EPHX2 | |
| SCHEMBL16380619 | 0.78 | HSD11B1 (0.46) | HSD11B1HSD11B2EPHX2 | |
| SCHEMBL12968026 | 0.78 | HSD11B1 (0.40) | HSD11B1HSD11B2EPHX2 | |
| SCHEMBL10234486 | 0.78 | HSD11B1 (0.40) | HSD11B1HSD11B2EPHX2 | |
| SCHEMBL12759956 | 0.78 | EPHX2 (0.47) | HSD11B1HSD11B2EPHX2 | |
| SCHEMBL25589736 | 0.78 | EPHX2 (0.47) | HSD11B1HSD11B2EPHX2 | |
| SCHEMBL19248218 | 0.78 | EPHX2 (0.47) | HSD11B1HSD11B2EPHX2 | |
| SCHEMBL24174762 | 0.77 | EPHX2 (0.33) | HSD11B1HSD11B2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230167104-A1 | NEW IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 | PERHA PHARMACEUTICALS (FR) | 2023-06-01 | — | — | US | disclosed |
| US-8895552-B2 | Cyclic amide derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2014-11-25 | — | — | US | disclosed |
| US-20130217692-A1 | CYCLIC AMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2013-08-22 | — | — | US | disclosed |
| EP-2612848-A1 | CYCLIC AMIDE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012029942-A1 | CYCLIC AMIDE DERIVATIVE | 大日本住友製薬株式会社 (JP) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130217692-A1 | CYCLIC AMIDE DERIVATIVE | HDAC10, H1-10, H1-0 | HSD11B1 583/4885HSD11B2 915/4885EPHX2 3856/4885 |
| US-20230167104-A1 | NEW IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 | CLK1, CLK2, CLK3 | HSD11B1 2758/4885HSD11B2 2773/4885EPHX2 4541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.